ES2039709T3 - Un procedimiento para preparar una composicion anticoagulante. - Google Patents

Un procedimiento para preparar una composicion anticoagulante.

Info

Publication number
ES2039709T3
ES2039709T3 ES198989100852T ES89100852T ES2039709T3 ES 2039709 T3 ES2039709 T3 ES 2039709T3 ES 198989100852 T ES198989100852 T ES 198989100852T ES 89100852 T ES89100852 T ES 89100852T ES 2039709 T3 ES2039709 T3 ES 2039709T3
Authority
ES
Spain
Prior art keywords
protein
anticoagulating
preparing
procedure
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989100852T
Other languages
English (en)
Spanish (es)
Inventor
Keizo Hirahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11897770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2039709(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of ES2039709T3 publication Critical patent/ES2039709T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES198989100852T 1988-01-28 1989-01-19 Un procedimiento para preparar una composicion anticoagulante. Expired - Lifetime ES2039709T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63015761A JP2739050B2 (ja) 1988-01-28 1988-01-28 抗血液凝固剤

Publications (1)

Publication Number Publication Date
ES2039709T3 true ES2039709T3 (es) 1993-10-01

Family

ID=11897770

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989100852T Expired - Lifetime ES2039709T3 (es) 1988-01-28 1989-01-19 Un procedimiento para preparar una composicion anticoagulante.

Country Status (13)

Country Link
US (1) US5084273A (OSRAM)
EP (1) EP0326014B1 (OSRAM)
JP (1) JP2739050B2 (OSRAM)
KR (1) KR0127754B1 (OSRAM)
AT (1) ATE74273T1 (OSRAM)
AU (1) AU607303B2 (OSRAM)
CA (1) CA1330299C (OSRAM)
DE (1) DE68901098D1 (OSRAM)
DK (1) DK37789A (OSRAM)
ES (1) ES2039709T3 (OSRAM)
GR (1) GR3005040T3 (OSRAM)
IE (1) IE63528B1 (OSRAM)
PT (1) PT89534B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
EP0651655A4 (en) 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
US5589516A (en) * 1993-04-05 1996-12-31 The Green Cross Corporation Liquid preparation of antithrombin-III and stabilizing method therefor
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5516889A (en) * 1993-06-21 1996-05-14 University Technologies International, Inc. Synthetic thrombin receptor peptides
WO1995030429A1 (en) * 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
JPH08224227A (ja) * 1995-02-22 1996-09-03 Internatl Reagents Corp 血液採血管
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
US6562781B1 (en) 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
WO1998055142A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
GB9711927D0 (en) * 1997-06-09 1997-08-06 Bristol Myers Squibb Co Compositions useful as fibrin sealants
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
EP1485121A4 (en) * 2002-03-08 2007-11-07 Lilly Co Eli ACTIVE C PROTEIN FORMULATIONS
WO2009096445A1 (ja) * 2008-01-29 2009-08-06 Kyowa Hakko Kirin Co., Ltd. 神経幹細胞増殖促進剤
CA3260876A1 (en) 2022-07-01 2024-01-04 Academisch Ziekenhuis Maastricht IMPROVED DOWNWARD REGULATION OF HISTONE CYTOTOXICITY BY A NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE COMPLEX

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism

Also Published As

Publication number Publication date
KR890011606A (ko) 1989-08-21
PT89534A (pt) 1989-10-04
JPH01193229A (ja) 1989-08-03
DE68901098D1 (de) 1992-05-07
DK37789A (da) 1989-07-29
GR3005040T3 (OSRAM) 1993-05-24
ATE74273T1 (de) 1992-04-15
EP0326014B1 (en) 1992-04-01
EP0326014A1 (en) 1989-08-02
AU2885589A (en) 1989-08-03
IE63528B1 (en) 1995-05-03
IE890269L (en) 1989-07-28
CA1330299C (en) 1994-06-21
US5084273A (en) 1992-01-28
AU607303B2 (en) 1991-02-28
JP2739050B2 (ja) 1998-04-08
KR0127754B1 (ko) 1998-04-01
PT89534B (pt) 2001-05-31
DK37789D0 (da) 1989-01-27

Similar Documents

Publication Publication Date Title
ES2039709T3 (es) Un procedimiento para preparar una composicion anticoagulante.
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
DE3684078D1 (de) Reinigung und aktivierung von proteinen aus unloeslichen einschlusskoerpern.
ES2087056T3 (es) 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
ATE133181T1 (de) Dehydrodidemnin b
ES2031849T3 (es) Procedimiento para la preparacion de un concentrado del factor v.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
NL970008I1 (nl) Derivaat van een weefselplasminogeenactivator.
ATE114319T1 (de) Produktion von proteinen in aktiven formen.
BR9607922A (pt) Produto medicamentoso final de uma proteína de plasma processos para preparar o produto medicamentoso final para melhorar a estabilidade de longo prazo de uma proteína de plasma e para tratar hemofilia e uso de um produto medicamentoso final
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
HUP9900506A2 (hu) Protrombinszármazékok
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
DE69705110D1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
ES2056149T3 (es) Ambliommina, una nueva sustancia activa para la terapia anticoagulante.
ES2067221T3 (es) Activador de plasminogeno del tejido que tiene propiedades especificas para la fibrina.
ES2060057T3 (es) Soluciones acuosas conteniendo proteina.
ES8601694A1 (es) Procedimiento para preparar un compuesto de inclusion a base de n,n-dimetil-2-cloro-5(3-metil-2-(fenilimino)-4-tiazolin-4-il)-fenilsulfonamida y b-ciclodextrina
DE3852118D1 (de) Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren.
KR880012237A (ko) 트롬빈 제제의 제조방법
FR2623628B1 (fr) Serum etalon, de nature humaine, reconstitue a partir des fractions rejetees (non utilisees en therapeutique), du fractionnement du plasma humain, du sang humain, du sang placentaire ou retroplacentaire
Lundberg Detection of drug abusers by urine screening

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 326014

Country of ref document: ES